Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases
Background - Brain metastases (BMs) are a key challenge in the management of anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC), but prognostic scores are complicated or rely on data before the era of tyrosine kinase inhibitors (TKIs). This study aimed to validate the nove...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 November 2023
|
| In: |
ESMO open
Year: 2023, Jahrgang: 8, Heft: 6, Pages: 1-7 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2023.102069 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.esmoop.2023.102069 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702923013108 
|
| Verfasserangaben: | I. Zerdes, C. Kamali, A. Koulouris, M. Elsayed, J. Schnorbach, P. Christopoulos, & G. Tsakonas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1888146591 | ||
| 003 | DE-627 | ||
| 005 | 20240703174518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240508s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2023.102069 |2 doi | |
| 035 | |a (DE-627)1888146591 | ||
| 035 | |a (DE-599)KXP1888146591 | ||
| 035 | |a (OCoLC)1443675781 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zerdes, Ioannis |e VerfasserIn |0 (DE-588)1328729028 |0 (DE-627)1888146583 |4 aut | |
| 245 | 1 | 0 | |a Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases |c I. Zerdes, C. Kamali, A. Koulouris, M. Elsayed, J. Schnorbach, P. Christopoulos, & G. Tsakonas |
| 264 | 1 | |c 20 November 2023 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.05.2024 | ||
| 520 | |a Background - Brain metastases (BMs) are a key challenge in the management of anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC), but prognostic scores are complicated or rely on data before the era of tyrosine kinase inhibitors (TKIs). This study aimed to validate the novel ALK-Brain Prognostic Index (ALK-BPI), which was originally proposed based on 44 TKI-treated ALK+ NSCLC patients from Karolinska University Hospital, using an external clinical cohort. - Patients and methods - TKI-treated ALK+ NSCLC patients with BM from Heidelberg (n = 82, cohort 1) were retrospectively analyzed alone and together with the original Karolinska cohort (n = 126, cohort 2). Cox regression models were used to determine the association of clinical variables and scores with overall survival (OS) after BM diagnosis (BM-related OS). - Results - Both cohorts showed a similar median age (58 years), roughly balanced sex distributions (52%-56% females), and Eastern Cooperative Oncology Group performance status (PS) 0-2 for most patients (87%-92%) at the time of BM development, which were present already at initial diagnosis in 36%-38% of the patients. Most patients had received next-generation ALK inhibitors (54%-63%), while 55%-56% of patients did not receive any radiotherapy. The ALK-BPI identified poor-risk patients (i.e. featuring ≥ 2/3 risk factors: PS > 2, male sex, development of BM after initial diagnosis) with a significantly shorter BM-related OS than other patients in both cohorts: 32/82 in cohort 1 with 21.3 versus 62.2 months in median [hazard ratio (HR) = 2.5, P < 0.001]; 59/126 in cohort 2 with 23.1 versus 67.2 months in median (HR = 2.6, P < 0.001). The five-parameter Lung-molGPA score did not achieve statistical significance and/or clear prognostic separation in all four groups, while the Disease-Specific Graded Prognostic Assessment score did not show consistent results. - Conclusions - The ALK-BPI is a reliable tool for easy prognostic dichotomization of TKI-treated ALK+ NSCLC patients with BM in daily clinical practice, without the complexity of previous models. | ||
| 650 | 4 | |a ALK-BPI | |
| 650 | 4 | |a brain metastases | |
| 650 | 4 | |a non-small-cell lung cancer | |
| 650 | 4 | |a prognosis | |
| 700 | 1 | |a Kamali, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koulouris, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a El Sayed, Mei |e VerfasserIn |0 (DE-588)1185583343 |0 (DE-627)1664958355 |4 aut | |
| 700 | 1 | |a Schnorbach, Johannes |d 1989- |e VerfasserIn |0 (DE-588)1201041112 |0 (DE-627)1684176174 |4 aut | |
| 700 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 700 | 1 | |a Tsakonas, G. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d [London] : Elsevier, 2016 |g 8(2023), 6, Artikel-ID 102069, Seite 1-7 |h Online-Ressource |w (DE-627)84705344X |w (DE-600)2844985-X |w (DE-576)454658516 |x 2059-7029 |7 nnas |a Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:6 |g elocationid:102069 |g pages:1-7 |g extent:7 |a Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.esmoop.2023.102069 |x Resolving-System |x Verlag |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2059702923013108 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240508 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PC138659702 |e 950000PC138659702 |e 950900PC138659702 |e 50000PC138659702 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 6 | ||
| 998 | |g 1201041112 |a Schnorbach, Johannes |m 1201041112:Schnorbach, Johannes |d 910000 |d 910100 |e 910000PS1201041112 |e 910100PS1201041112 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1185583343 |a El Sayed, Mei |m 1185583343:El Sayed, Mei |d 910000 |d 950000 |d 950900 |e 910000PE1185583343 |e 950000PE1185583343 |e 950900PE1185583343 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 4 | ||
| 999 | |a KXP-PPN1888146591 |e 4521697224 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1888146591","note":["Gesehen am 08.05.2024"],"name":{"displayForm":["I. Zerdes, C. Kamali, A. Koulouris, M. Elsayed, J. Schnorbach, P. Christopoulos, & G. Tsakonas"]},"relHost":[{"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"eki":["84705344X"],"zdb":["2844985-X"],"issn":["2059-7029"]},"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"title":[{"title_sort":"ESMO open","title":"ESMO open","subtitle":"cancer horizons"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2023","extent":"7","issue":"6","volume":"8","pages":"1-7","text":"8(2023), 6, Artikel-ID 102069, Seite 1-7"},"origin":[{"publisher":"Elsevier ; BMJ","dateIssuedKey":"2016","dateIssuedDisp":"2016-","publisherPlace":"[London] ; London"}],"name":{"displayForm":["European Society for Medical Oncology"]},"pubHistory":["1.2016 -"],"note":["Gesehen am 13.06.24"],"recId":"84705344X","disp":"Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastasesESMO open"}],"person":[{"family":"Zerdes","display":"Zerdes, Ioannis","given":"Ioannis","role":"aut"},{"given":"C.","display":"Kamali, C.","family":"Kamali","role":"aut"},{"role":"aut","given":"A.","family":"Koulouris","display":"Koulouris, A."},{"display":"El Sayed, Mei","family":"El Sayed","given":"Mei","role":"aut"},{"role":"aut","given":"Johannes","display":"Schnorbach, Johannes","family":"Schnorbach"},{"role":"aut","family":"Christopoulos","display":"Christopoulos, Petros","given":"Petros"},{"display":"Tsakonas, G.","family":"Tsakonas","given":"G.","role":"aut"}],"physDesc":[{"extent":"7 S."}],"title":[{"title_sort":"Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases","title":"Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases"}],"id":{"eki":["1888146591"],"doi":["10.1016/j.esmoop.2023.102069"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"20 November 2023"}]} | ||
| SRT | |a ZERDESIOANVALIDATION2020 | ||